We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.58B
AUM Growth
+$79.4M
Cap. Flow
-$279M
Cap. Flow %
-2.91%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$158M
2
MOH icon
Molina Healthcare
MOH
+$98.2M
3
MRK icon
Merck
MRK
+$95.1M
4
ZBH icon
Zimmer Biomet
ZBH
+$88.5M
5
MDVN
MEDIVATION, INC.
MDVN
+$85.1M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$182M
2
CELG
Celgene Corp
CELG
+$142M
3
HCA icon
HCA Healthcare
HCA
+$129M
4
AGN.PRA
Allergan plc
AGN.PRA
+$87M
5
TSRO
TESARO, Inc.
TSRO
+$84.2M

Sector Composition

Rank Sector Weight
1 Healthcare 89.03%
2 Financials 0.34%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
51
Edwards Lifesciences
EW
$49.2B
$51M 0.53%
1,534,200
+1,189,200
+345% +$40.7M
LOXO
52
DELISTED
Loxo Oncology, Inc
LOXO
$50.4M 0.53%
2,175,857
– –
CI icon
53
Cigna
CI
$78.8B
$42.2M 0.44%
329,600
-5,900
-2% -$779K
SPY icon
54
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$777B
$41.9M 0.44%
+200,000
New +$41.5M
INSM icon
55
Insmed
INSM
$22.7B
$41M 0.43%
4,158,600
+688,700
+20% +$8.04M
XBI icon
56
State Street SPDR S&P Biotech ETF
XBI
$10B
$40.3M 0.42%
745,300
-235,900
-24% -$12.9M
EGRX
57
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$40.2M 0.42%
+1,036,100
New +$43.1M
ARRY
58
DELISTED
Array Biopharma Inc
ARRY
$39.1M 0.41%
10,973,900
+284,900
+3% +$928K
DVAX
59
DELISTED
Dynavax Technologies
DVAX
$35M 0.37%
2,403,300
+428,600
+22% +$7.32M
AGN
60
CALL
DELISTED
Allergan plc
AGN
$34.7M 0.36%
150,000
+50,000
+50% +$11.5M
ITCI
61
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$34.4M 0.36%
885,400
+591,400
+201% +$21.3M
VRAY
62
DELISTED
ViewRay, Inc.
VRAY
$32.7M 0.34%
7,989,916
– –
DMTX
63
DELISTED
Dimension Therapeutics, Inc
DMTX
$32.4M 0.34%
5,397,698
– –
OTIC
64
DELISTED
Otonomy, Inc.
OTIC
$29.4M 0.31%
1,850,094
– –
ASND icon
65
Ascendis Pharma A/S
ASND
$16.8B
$29.1M 0.3%
2,191,000
+1,968,777
+886% +$30.3M
IOVA icon
66
Iovance Biotherapeutics
IOVA
$2.04B
$27.4M 0.29%
3,382,900
+2,360,800
+231% +$14.8M
EXAS
67
DELISTED
Exact Sciences
EXAS
$26.1M 0.27%
2,131,200
+240,800
+13% +$1.81M
RNAC icon
68
Cartesian Therapeutics
RNAC
$223M
$25.8M 0.27%
+61,427
New +$25.8M
SYK icon
69
Stryker
SYK
$134B
$25.4M 0.27%
212,000
– –
THC icon
70
Tenet Healthcare
THC
$22.2B
$25.3M 0.26%
+915,300
New +$27M
SGYP
71
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$22.7M 0.24%
5,976,648
+3,700,000
+163% +$12.5M
LKFT
72
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$19.6M 0.2%
352,700
+122,700
+53% +$6.17M
IMGN
73
DELISTED
Immunogen Inc
IMGN
$18.8M 0.2%
6,095,647
– –
EHTH icon
74
eHealth
EHTH
$42.5M
$18.2M 0.19%
1,300,000
– –
LUMO
75
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$17.8M 0.19%
175,723
+84,945
+94% +$10.5M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.58B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q2 2016 filing shows 16 new, 39 increased, 32 reduced and 21 closed positions. Its largest new stake was Molina Healthcare: 1,838,000 shares worth $91.7M. The largest sale was Bristol-Myers Squibb, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.58B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.58B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.